Cancer Medicine (Feb 2023)
The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis
- Takeshi Hatanaka,
- Atsushi Naganuma,
- Atsushi Hiraoka,
- Toshifumi Tada,
- Masashi Hirooka,
- Kazuya Kariyama,
- Joji Tani,
- Masanori Atsukawa,
- Koichi Takaguchi,
- Ei Itobayashi,
- Shinya Fukunishi,
- Kunihiko Tsuji,
- Toru Ishikawa,
- Kazuto Tajiri,
- Hironori Ochi,
- Satoshi Yasuda,
- Hidenori Toyoda,
- Chikara Ogawa,
- Takashi Nishimura,
- Noritomo Shimada,
- Kazuhito Kawata,
- Hisashi Kosaka,
- Satoru Kakizaki,
- Takaaki Tanaka,
- Hideko Ohama,
- Kazuhiro Nouso,
- Asahiro Morishita,
- Akemi Tsutsui,
- Takuya Nagano,
- Norio Itokawa,
- Tomomi Okubo,
- Taeang Arai,
- Michitaka Imai,
- Yohei Koizumi,
- Shinichiro Nakamura,
- Masaki Kaibori,
- Hiroko Iijima,
- Yoichi Hiasa,
- Takashi Kumada,
- the Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Affiliations
- Takeshi Hatanaka
- Department of Gastroenterology Gunma Saiseikai Maebashi Hospital Maebashi Gunma Japan
- Atsushi Naganuma
- Department of Gastroenterology National Hospital Organization Takasaki General Medical Center Takasaki Japan
- Atsushi Hiraoka
- Gastroenterology Center Ehime Prefectural Central Hospital Matsuyama Japan
- Toshifumi Tada
- Department of Internal Medicine Japanese Red Cross Himeji Hospital Himeji Japan
- Masashi Hirooka
- Department of Gastroenterology and Metabology Ehime University Graduate School of Medicine Ehime Japan
- Kazuya Kariyama
- Department of Gastroenterology Okayama City Hospital Okayama Japan
- Joji Tani
- Department of Gastroenterology and Hepatology Kagawa University Kagawa Japan
- Masanori Atsukawa
- Division of Gastroenterology and Hepatology, Department of Internal Medicine Nippon Medical School Tokyo Japan
- Koichi Takaguchi
- Department of Hepatology Kagawa Prefectural Central Hospital Takamatsu Japan
- Ei Itobayashi
- Department of Gastroenterology Asahi General Hospital Asahi Japan
- Shinya Fukunishi
- Premier Departmental Research of Medicine Osaka Medical and Pharmaceutical University Osaka Japan
- Kunihiko Tsuji
- Center of Gastroenterology Teine Keijinkai Hospital Sapporo Japan
- Toru Ishikawa
- Department of Gastroenterology Saiseikai Niigata Hospital Niigata Japan
- Kazuto Tajiri
- Department of Gastroenterology Toyama University Hospital Toyama Japan
- Hironori Ochi
- Center for Liver‐Biliary‐Pancreatic Disease Matsuyama Red Cross Hospital Matsuyama Japan
- Satoshi Yasuda
- Department of Gastroenterology and Hepatology Ogaki Municipal Hospital Ogaki Japan
- Hidenori Toyoda
- Department of Gastroenterology and Hepatology Ogaki Municipal Hospital Ogaki Japan
- Chikara Ogawa
- Department of Gastroenterology Japanese Red Cross Takamatsu Hospital Takamatsu Japan
- Takashi Nishimura
- Division of Gastroenterology and Hepatology, Department of Internal Medicine Hyogo Medical University Nishinomiya Japan
- Noritomo Shimada
- Division of Gastroenterology and Hepatology Otakanomori Hospital Kashiwa Japan
- Kazuhito Kawata
- Hepatology Division, Department of Internal Medicine II Hamamatsu University School of Medicine Hamamatsu Japan
- Hisashi Kosaka
- Department of Surgery Kansai Medical University Hirakata Japan
- Satoru Kakizaki
- Department of Clinical Research National Hospital Organization Takasaki General Medical Center Takasaki Japan
- Takaaki Tanaka
- Gastroenterology Center Ehime Prefectural Central Hospital Matsuyama Japan
- Hideko Ohama
- Gastroenterology Center Ehime Prefectural Central Hospital Matsuyama Japan
- Kazuhiro Nouso
- Department of Gastroenterology Okayama City Hospital Okayama Japan
- Asahiro Morishita
- Department of Gastroenterology and Hepatology Kagawa University Kagawa Japan
- Akemi Tsutsui
- Department of Hepatology Kagawa Prefectural Central Hospital Takamatsu Japan
- Takuya Nagano
- Department of Hepatology Kagawa Prefectural Central Hospital Takamatsu Japan
- Norio Itokawa
- Division of Gastroenterology and Hepatology, Department of Internal Medicine Nippon Medical School Tokyo Japan
- Tomomi Okubo
- Division of Gastroenterology and Hepatology, Department of Internal Medicine Nippon Medical School Tokyo Japan
- Taeang Arai
- Division of Gastroenterology and Hepatology, Department of Internal Medicine Nippon Medical School Tokyo Japan
- Michitaka Imai
- Department of Gastroenterology Saiseikai Niigata Hospital Niigata Japan
- Yohei Koizumi
- Department of Gastroenterology and Metabology Ehime University Graduate School of Medicine Ehime Japan
- Shinichiro Nakamura
- Department of Internal Medicine Japanese Red Cross Himeji Hospital Himeji Japan
- Masaki Kaibori
- Department of Surgery Kansai Medical University Hirakata Japan
- Hiroko Iijima
- Division of Gastroenterology and Hepatology, Department of Internal Medicine Hyogo Medical University Nishinomiya Japan
- Yoichi Hiasa
- Department of Gastroenterology and Metabology Ehime University Graduate School of Medicine Ehime Japan
- Takashi Kumada
- Department of Nursing Gifu Kyoritsu University Ogaki Japan
- the Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
- DOI
- https://doi.org/10.1002/cam4.5294
- Journal volume & issue
-
Vol. 12,
no. 4
pp. 4259 – 4269
Abstract
Abstract Aim This study investigated whether or not the hepatocellular carcinoma modified Gustave Roussy Immune Score (HCC‐GRIm‐Score) serves as a prognostic indicator for HCC patients treated with atezolizumab and bevacizumab (Atez/Bev). Methods A total of 405 HCC patients who received Atez/Bev from September 2020 to January 2022 at 22 different institutions were included in this retrospective study. The HCC‐GRIm score was based on the combination of the albumin level (<3.5 g/L = 1 point), lactate dehydrogenase (≥245 U/L = 1 point), neutrophil‐to‐lymphocyte ratio (≥4.8 = 1 point), aspartate aminotransferase‐to‐alanine aminotransferase ratio (≥1.44 = 1 point), and total bilirubin level (≥1.3 mg/dl = 1 point). Patients were divided into the low‐score group (0, 1, or 2 points) and the high‐score group (3, 4, or 5 points). Results There were 89 (22.0%), 141 (34.8%), 106 (26.2%), 49 (12.1%), 16 (4.0%), and 4 (1.0%) patients with scores of 0, 1, 2, 3, 4, 5, respectively. The progression‐free survival (PFS) in the low‐score group was significantly longer than that in the high‐score group (median 7.8 vs. 3.5 months, p < 0.001). The median overall survival (OS) of the low‐score group was not reached at the time cutoff, with a 1‐year survival rate of 75.5%, whereas the median OS of the high‐score group was 8.5 months, showing a significant difference (p < 0.001). A high HCC‐GRIm score was a significant unfavorable factor associated with the PFS and OS in multivariate analyses (p = 0.002 and p < 0.001, respectively). Conclusions The HCC‐GRIm score serves as a novel prognostic score for HCC patients treated with Atez/Bev.
Keywords
- aspartate transaminase‐to‐alanine transaminase ratio
- atezolizumab and bevacizumab
- HCC‐GRIm score
- hepatocellular carcinoma
- lactate dehydrogenase
- neutrophil‐to‐lymphocyte ratio
